Gregory George Acquires 5,034,129 Shares of Mesoblast Limited (ASX:MSB) Stock

Mesoblast Limited (ASX:MSB) insider Gregory George acquired 5,034,129 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was acquired at an average cost of A$2.95 ($1.85) per share, for a total transaction of A$14,830,544.03 ($9,327,386.18).

Mesoblast Stock Performance

The company has a debt-to-equity ratio of 24.76, a quick ratio of 1.82 and a current ratio of 1.18. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -23.29, a P/E/G ratio of 9.56 and a beta of 2.38.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.